Proinsulin C-peptide (55-89), human - 0.5 mg
|
|
11097-48-6
|
Protease-Activated Receptor-4, PAR-4 Agonist, amide
|
|
352017-71-1
|
Protease-Activated Receptor-4, PAR-4 Antagonist, amide - 1 mg
|
|
327177-34-4
|
Proadrenomedullin N-term peptide, PAMP (1-20) - 5 mg
|
|
150238-87-2
|
PrP (106-126), prion protein - 1 mg
|
|
148439-49-0
|
Protease-Activated Receptor-2, PAR-2 Agonist, amide - 1 mg
|
|
729589-58-6
|
SARS-CoV-2 Spike receptor binding domain, RBD (371-394) - 0.5 mg
|
|
|
SARS-CoV-2 Spike receptor binding domain, RBD (395-430) - Lys(Biotin-LC) - 0.1 mg
|
|
|
Protease-Activated Receptor-2, PAR-2 Agonist 2, amide - 5 mg
|
|
190383-13-2
|
Recombinant mouse MOG (1-125)
|
|
|
Renin FRET substrate, Dabcyl/EDANS - 1 mg
|
|
142988-22-5
|
Renin Substrate, Angiotensinogen (1-14), rat - 1 mg
|
|
110200-37-8
|
SARS-CoV-2 Spike receptor binding domain, RBD (523-541) - Lys(Biotin-LC) - 0.1 mg
|
|
|
Protein A-Biotin Conjugate - 5 mg
|
|
|
R-PE (R-Phycoerythrin) - 1 mg
|
|
|
Recombinant rat MOG (1-125)
|
|
|
Protease-Activated Receptor-4, PAR-4 Agonist 3, amide, murine - 1 mg
|
|
245443-52-1
|
Prodan [6-Propionyl-2-dimethylaminonaphthalene] - 25 mg
|
|
70504-01-7
|
Resorufin -D-Galactopyranoside - 25 mg
|
|
95079-19-9
|
SAMs peptide, FAM labeled - 1 mg
|
|
|
Protease-Activated Receptor-3, PAR-3 (1-6), human - 1 mg
|
|
1872435-09-0
|
Poly-gamma-D-Glutamic Acid Construct - 1 mg
|
|
|
PSTi8, 1mg
|
|
|
Rhod-2, AM UltraPure Grade - 1 mg
|
|
145037-81-6
|
Proinsulin C-peptide (55-87), porcine - 0.5 mg
|
|
28152-90-1
|
RGD-4C - 5 mg
|
|
|
Rhodopsin Epitope Tag - 5 mg
|
|
|
Protease-Activated Receptor-1, PAR-1 Antagonist 1 - 1 mg
|
|
149440-16-4
|
Pramlintide, Acetate [Pro25, 28, 29]-Amylin(1-37), human, Amide - 1 mg
|
|
196078-30-5
|
RGDS - 5 mg
|
|
91037-65-9
|
Protease-Activated Receptor-3, PAR-3 Agonist, amide - 1 mg
|
|
261521-21-5
|
RH414 - 5 mg
|
|
161433-30-3
|
pro-NPY peptide (34-43), human - 0.1 mg
|
|
|
Rev4
|
|
|
Propidium iodide, 1.0 mg/mL solution in water - 10 ml
|
|
25535-16-4
|
pp60(v-SRC) Autophosphorylation Site, Phosphorylated - 1 mg
|
|
|
Protein A-HiLyte Fluor 647 Conjugate - 1 mg
|
|
|
Protegrin-1 (PG-1), amide
|
|
|
SARS-CoV Peptide Antigen Positive control - 1mg NET peptide
|
|
|
Prosaptide TX14(A)
|
|
196391-82-9
|
Quinine sulfate Fluorescence Reference Standard - 100 mg
|
|
6119-70-6
|
Protease-Activated Receptor-1, PAR-1 Agonist 1, amide - 5 mg
|
|
|
Recombinant human MOG (1-125)
|
|
|
SARS-CoV-2 Spike receptor binding domain, RBD (319-335) -Lys(Biotin-LC) - 0.1 mg
|
|
|
SARS-CoV-2 Spike receptor binding domain, RBD (348-357)- Lys(Biotin-LC) - 0.1 mg
|
|
|
SARS-CoV T-cell Peptide Antigens Set - 0.25 mg Net
|
|
|
PMAP-23
|
|
|
SARS - CoV - 2 Spike RBM (receptor binding motif), 438 - 458 - 0.5 mg
|
|
|
Pluronic? F-127 Cell Culture Tested - 10 g
|
|
9003-11-6
|
Proapoptotic Peptide, (klaklak)2, 5-FAM-labeled - 1 mg
|
|
|
QXL? 490 acid, SE - 5 mg
|
|
|
S6 Kinase Substrate (229-239)
|
|
|
Ryanodine receptor 1 (RyR1) (3614-3643), Calmodulin Binding Peptide (CaMBP) - 1 mg
|
|
|
S3 Fragment, ADF/cofilin, LIMK1 substrate - 1 mg
|
|
|
QXL? 670 acid, SE - 5 mg
|
|
|
Pluronic? F-127, 10 % solution in water - 100 ml
|
|
|
SARS-CoV-2 Spike receptor binding domain, RBD (319-335) - 0.5 mg
|
|
|
QXL? 570 acid - 10 mg
|
|
|
Renin Substrate, Angiotensinogen (1-14), human - 1 mg
|
|
104180-23-6
|
SARS-CoV-2 Spike receptor binding domain, RBD (513-520) - Lys(Biotin-LC) - 0.1 mg
|
|
|
SARS-CoV-2 Spike receptor binding domain, RBD (513-520) - 0.5 mg
|
|
|
RS domain derived peptide - 1 mg
|
|
|
SARS-CoV-2 Spike receptor binding domain, RBD (352-365) - Lys(Biotin-LC) - 0.1 mg
|
|
|
SARS-CoV-2 Spike receptor binding domain, RBD (395-430) - 0.5 mg
|
|
|
SAMS Peptide [HMRSAMSGLHLVKRR-NH2] - 5 mg
|
|
|
pVEC (Cadherin-5) - 1 mg
|
|
|
S6 Kinase Substrate (229-239), Amide, Biotinalyted - 1 mg
|
|
|
SARS-CoV-2 Spike receptor binding domain, RBD (523-541) - 0.5 mg
|
|
|
SARS-CoV Peptide Antigen Negative control - 1mg NET peptide
|
|
|
Protein A-HiLyte Fluor 488 Conjugate - 1 mg
|
|
|
SARS-CoV-2 Spike receptor binding domain, RBD (348-357) - 0.5 mg
|
|
|
SARS - CoV - 2 Spike RBM (receptor binding motif), 480 - 496 - 0.5 mg
|
|
|
Renin FRET Substrate, R-E(EDANS)--K(Dabcyl) - 1 mg
|
|
791068-69-4
|
Protease-Activated Receptor-1, PAR-1 Agonist - 1 mg
|
|
|
Protease-Activated Receptor-1, PAR-1 Antagonist 2, amide - 1 mg
|
|
|
SARS-CoV-2 Spike receptor binding domain, RBD (336-347) - 0.5 mg
|
|
|
SARS - CoV - 2 Spike RBM (receptor binding motif), 500 - 509 - 0.5 mg
|
|
|
SARS-CoV-2 Spike receptor binding domain, RBD (352-365) - 0.5 mg
|
|
|
Protein A-HiLyte Fluor 750 Conjugate - 1 mg
|
|
|
SARS-CoV-2 Spike receptor binding domain, RBD (336-347) - Lys(Biotin-LC) - 0.1 mg
|
|
|
Protein A-HiLyte Fluor 555 Conjugate - 1 mg
|
|
|
Rabies Virus Glycoprotein (RVG) - 1 mg
|
|
|
Pyrrhocoricin - 1 mg
|
|
156548-23-1
|
Renin Inhibitor Peptide, WFML Peptide, rat - 1 mg
|
|
|
Protease-Activated Receptor-1, PAR-1 Agonist 2, amide - 1 mg
|
|
|
Protease-Activated Receptor-1, PAR-1 Agonist 3, amide - 1 mg
|
|
|
Pluronic? F-127, 20 % solution in DMSO - 10 ml
|
|
|
QXL? 570 acid, SE - 5 mg
|
|
|
SARS-CoV-2 Spike receptor binding domain, RBD (371-394) - Lys(Biotin-LC) - 0.1 mg
|
|
|
Rat Renin, recombinant - 20 μg
|
|
|
QXL? 570 C2 maleimide - 5 mg
|
|
|
Renin FRET Substrate (5-FAM/QXL? 520), rat - 0.1 mg
|
|
|
QXL? 490 acid - 10 mg
|
|
|
SARS-CoV Peptide Antigen I - 1mg NET peptide
|
|
|
Renin FRET Substrate (5-FAM/QXL? 520) - 0.1 mg
|
|
|
Prostatic Acid Phosphatase (248-286), PAP (248-286) - 1 mg
|
|
|
PUMA BH3 - 1 mg
|
|
|
Proapoptotic Peptide, (klaklak)2 - 1 mg
|
|
|
Proteases Substrate, Fluorogenic, (Z-R)2Rh1102HCl - 5 mg
|
|
|
SARS - CoV - 2 Spike RBM (receptor binding motif), 450 - 473 - 0.5 mg
|
|
|